Dyslipidemia associated with chronic kidney disease - Wikidata - awgldk - TriplyDB

Dyslipidemia associated with chronic kidney disease

Dyslipidemia associated with chronic kidney disease

http://www.wikidata.org/entity/Q35020237

about

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes The effects of tai chi on the renal and cardiac functions of patients with chronic kidney and cardiovascular diseases.Chronic kidney diseases in mixed ancestry south African populations: prevalence, determinants and concordance between kidney function estimators.Thyroid dysfunction and dyslipidemia in chronic kidney disease patients.The Predictive Role of Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio According to Renal Function in Patients with Acute Myocardial Infarction.Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients.Dyslipidemia in patients with chronic kidney disease: etiology and management.Unusual Dyslipidemia in Patients with Chronic Kidney Diseases.Fenofibrate and the kidney: an overview.Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.PCSK9 in chronic kidney disease.Volume status in patients on peritoneal dialysis: the role of apelin and bio-impedance spectroscopy.Cardiac Autonomic Neuropathy Predicts All-Cause and Cardiovascular Mortality in Patients With End-Stage Renal Failure: A 5-Year Prospective Study.New perspectives on CKD-induced dyslipidemia.Location-Specific Oral Microbiome Possesses Features Associated With CKD.Erythrocyte Membrane Bound ATPase and Antioxidant Enzyme Changes Associated with Vascular Calcification is Reduced by Sodium Thiosulfate.Dyslipidemia in people living with HIV-AIDS in a tertiary hospital in South-East Nigeria.oxLDL inhibits differentiation and functional activity of osteoclasts via scavenger receptor-A mediated autophagy and cathepsin K secretion

P2860

Q33889894-2388DD0D-6333-4C18-AB7A-8083785E5C6C Q34567227-9AEB1B97-EAD4-4F75-AA40-45AFC77C3ADA Q34645250-6F25797F-216F-4068-9AB3-C13707774C80 Q35824971-0EAAC6FB-F90D-47C7-BDA1-3A822058338F Q36176359-80FF0EFB-741B-46AF-A04D-B55103CFB396 Q36538088-FADFF754-9CC2-4FED-8D39-7727C8D4528E Q37470972-7DC59232-39E4-466B-A2DB-C8D072C246E2 Q37638707-4EF37D38-C15C-4D11-B019-4E406CF04108 Q37663597-4AF8E9F6-CE1D-41DC-87D6-592F37756652 Q38088377-5F7BDC2F-BB90-465A-A808-15DBD8520B25 Q38208727-90768F0D-88DB-4E3D-9D8F-6ED8411E89E7 Q38389206-6398180A-661C-4451-B850-5BD5B19595AF Q38400031-528FA96F-045E-44C4-ABA2-73C206947110 Q39022581-605D9215-3991-4FDC-BDDC-D1EF665184E0 Q39570040-21FE6A41-D705-457E-9142-D131F06BD110 Q43708947-0C44A7A1-D679-4EE7-8F3A-002008724F7F Q47922360-FF84BF92-5B64-4B0F-B05B-88D5F7CD2EDE Q50016244-B7761ECD-1117-4FB3-9DCB-4911EB400A32 Q50073111-8A71B9E0-CB67-4FE9-906A-169CB3338583 Q52722140-D4822EFD-4679-4231-B191-CE24B00D4C43 Q58803602-166B158B-6DBC-4101-8F20-BD0019174077

P2860

Dyslipidemia associated with chronic kidney disease

http://www.wikidata.org/entity/Q35020237

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dyslipidemia associated with chronic kidney disease

@ast

Dyslipidemia associated with chronic kidney disease

@en

type

label

Dyslipidemia associated with chronic kidney disease

@ast

Dyslipidemia associated with chronic kidney disease

@en

prefLabel

Dyslipidemia associated with chronic kidney disease

@ast

Dyslipidemia associated with chronic kidney disease

@en

P1433

Q35020237-76B3353F-D0CE-48DF-87FC-F6CB4685C2CF

P1476

Q35020237-6AC29A66-1B4C-40D0-8D5B-7D64DD2BCFAC

P2093

Q35020237-711DEF7C-E527-44F9-8A37-87B521EFA9EF

Q35020237-9C31BA1F-4092-496D-85CA-A934D1D0475C

Q35020237-FE1715DE-9AC2-48E9-ADDF-925D1B620ED5

P2860

Q35020237-02887204-DB9E-4ABB-B85B-593F7FC76892

Q35020237-041CFC76-406C-4AB5-BB24-93AE8B5DA875

Q35020237-0EAE72CB-426D-4A69-B240-0EEF2782C4EA

Q35020237-0F449D02-EEFA-465C-90C9-468754DFCCEB

Q35020237-155BD271-72B2-4598-90BF-6862F580D5BD

Q35020237-15B455C6-1CF4-46A3-A5C5-B2BCF29B460F

Q35020237-1A1C4292-6CC3-41E6-B38C-666A362D6C56

Q35020237-1A708262-6D41-403E-B04D-F0F179EA9C20

Q35020237-1D748D7A-D8F3-413B-8F5A-4E9BDFB8E4E9

Q35020237-1D8749B1-A849-4443-B98A-23A2B0AC5F02

P304

Q35020237-8D0B3CBC-85BB-46E8-B43B-38B56703D750

P31

Q35020237-C30E85BB-1CB2-4DC9-80CC-EDC28A4299C2

P356

Q35020237-AB8702C5-6218-4B7C-8D5E-5893FDE9A00F

P478

Q35020237-A6D78F3F-85B2-4196-BA63-B5FB9BEB512D

P577

Q35020237-CD958663-1B92-467B-98FE-8C1982C3B070

P5875

Q35020237-0C7E6388-8120-47E3-9EDA-8C83E9849E6C

P698

Q35020237-7F83D771-0194-448C-930A-E49E709F301B

P921

Q35020237-F00C8F8F-C9B4-4B7D-88D2-8DA7F8C44BEC

P932

Q35020237-C88C1E16-AA41-435C-851E-F797A3D0ABB4

P356

1874192401105010041

P1433

Open Cardiovascular Medicine Journal

P1476

Dyslipidemia associated with chronic kidney disease

@en

P2093

Moses Elisaf

http://www.w3.org/2001/XMLSchema#string

Vasilis Tsimihodimos

http://www.w3.org/2001/XMLSchema#string

Zoi Mitrogianni

http://www.w3.org/2001/XMLSchema#string

P2860

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Safety considerations with fibrate therapy.

P304

41-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1874192401105010041

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51193728

http://www.w3.org/2001/XMLSchema#string

P698

21643500

http://www.w3.org/2001/XMLSchema#string

P921

P932

3106357

http://www.w3.org/2001/XMLSchema#string